ArticleCancers2010
Serum biomarkers for early detection of gynecologic cancers.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Adenomyosis-associated uterine rupture and pulmonary endometriosis mimicking advanced-stage uterine malignancy in an adolescent female: A case report.World journal of clinical cases · 2025Article
- Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review.Cancers · 2023Review
- Integrated analysis identifies RAC3 as an immune-related prognostic biomarker associated with chemotherapy sensitivity in endometrial cancer.Journal of cellular and molecular medicine · 2023Article
- Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.Analytical and bioanalytical chemistry · 2023Article
- Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer.Genes & cancer · 2022Article
- Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer.Metabolites · 2020Review
- Article
- Coordination of Nanoconjugation with an Antigen/Antibody for Efficient Detection of Gynecological Tumors.Journal of analytical methods in chemistry · 2020Article
- Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.Scientific reports · 2019Article
- Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2.International journal of oncology · 2019Article
- Identification of candidate target genes for endometrial cancer, such as ANO1, using weighted gene co-expression network analysis.Experimental and therapeutic medicine · 2019Article
- Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer.Oncology letters · 2018Article
- Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The use of optical spectroscopy for in vivo detection of cervical pre-cancer.Lasers in medical science · 2014Review
- The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Detection of differential levels of proteins in the urine of patients with endometrial cancer: analysis using two-dimensional gel electrophoresis and o-glycan binding lectin.International journal of molecular sciences · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28-85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.